Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression

Journal of Affective Disorders
Samuel T WilkinsonSanjay J Mathew

Abstract

Serum brain-derived neurotrophic factor (BDNF) is decreased in individuals with major depressive disorder (MDD). Pre-clinical and clinical reports suggest that the glutamate release inhibitor riluzole increases BDNF and may have antidepressant properties. Here we report serum (sBDNF) and plasma (pBDNF) levels from a randomized controlled, adjunctive, sequential parallel comparison design trial of riluzole in MDD. Serum and plasma BDNF samples were drawn at baseline and weeks 6 and 8 from 55 subjects randomized to adjunctive treatment with riluzole or placebo for 8 weeks. Riluzole responders had lower baseline serum (19.08 ng/ml [SD 9.22] v. 28.80 ng/ml [9.63], p = 0.08) and plasma (2.72 ng/ml [1.07] v. 4.60 ng/ml [1.69], p = 0.06) BDNF compared to non-responders at a trend level. This pattern was nominally seen in placebo responders for baseline pBDNF to some degree (1.21 ng/ml [SD 1.29] v. 3.58 ng/ml [SD 1.67], p = 0.12) but not in baseline sBDNF. A number of limitations warrant comment, including the small sample size of viable BDNF samples and the small number of riluzole responders. Preliminary evidence reported here suggests that lower baseline BDNF may be associated with better clinical response to riluzole.

References

Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·E S LevineM R Plummer
Jul 1, 1997·Archives of General Psychiatry·R S DumanE J Nestler
Aug 3, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Ritsuko Katoh-SembaKanefusa Kato
May 17, 2005·Brain Research. Molecular Brain Research·Félicien KaregeRomano La Harpe
Jun 22, 2005·Proceedings of the National Academy of Sciences of the United States of America·Rupshi MitraSumantra Chattarji
Aug 29, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jing DuHusseini K Manji
Sep 14, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Christopher Pittenger, Ronald S Duman
Feb 20, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Yan-Feng ZouFang-Fang Liao
Mar 26, 2010·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Luisella Bocchio-ChiavettoMassimo Gennarelli
Aug 13, 2010·Psychoneuroendocrinology·B A A BusR C Oude Voshaar
Oct 5, 2011·Reviews in the Neurosciences·Daniel J ChristoffelScott J Russo
May 30, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sanjay J MathewGerard Sanacora

❮ Previous
Next ❯

Citations

Mar 14, 2019·Current Pharmaceutical Design·Carmine TomasettiDomenico D Berardis
Jun 25, 2019·Frontiers in Psychology·Raíssa Nóbrega de AlmeidaNicole Leite Galvão-Coelho
Apr 3, 2019·Experimental and Therapeutic Medicine·Zheng GuYaqiong Han
Oct 15, 2019·Expert Opinion on Investigational Drugs·Bella SchanzerSanjay J Mathew
May 16, 2020·Frontiers in Behavioral Neuroscience·Giuliana Travassos Pires SantiagoNicole Leite Galvão-Coelho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.